<DOC>
	<DOCNO>NCT02228421</DOCNO>
	<brief_summary>This phase IV multicenter trial evaluate pharmacoeconomic ( PE ) impact crizotinib companion diagnostic test use real-life setting advance ALK-positive non-small cell lung cancer ( NSCLC ) patient . NSCLC represent 80 % new case lung cancer . One molecular subtype NSCLC ALK-positive subtype . The anaplastic lymphoma kinase ( ALK ) transmembrane receptor tyrosine kinase . Activation ALK occur formation gene fusion NSCLC , gene fusion partner ALK primarily EML4 . The result fusion protein capable activate ALK kinase domain , lead cell growth . The estimated prevalence ALK rearrangements NSCLC 3-5 % , commonly find amongst patient adenocarcinoma histology , never smoker know wild type EGFR KRAS . Crizotinib potent inhibitor ALK approve treatment advance ALK+ NSCLC patient . This example personalize medicine , patient select treatment base upon molecular assay , provide specific therapy ( crizotinib ) disease . The pharmacoeconomic impact use genetic information early treatment decision NSCLC determine . The study enable real-life Heath Economics Outcome Research ( HEOR ) . Approximately 90 patient recruit . Patients ask complete quality-of-life questionnaire regular interval real-life set treatment crizotinib .</brief_summary>
	<brief_title>Study Evaluate Real-world Pharmacoeconomics Crizotinib NSCLC Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Patients histologically confirm locally advanced metastatic NSCLC Presence ALKfusion oncogene ( ALK+ ) determine use validated test platform Planned first secondline treatment crizotinib Signed date IRBapproved informed consent document Ability read understand English French 18 year age old</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>